A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
← catalyst calendarNCT06985147 · readout ≤ 193 d
Sponsored by Disc Medicine, Inc (industry) · IRON — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60estimated
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-12 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Polycythemia Vera (PV)
Intervention
- Drug: DISC-3405
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with treatment-related adverse events as assessed by CTCAE
measured Up to 365 days
Incidence of clinically abnormal vital signs
measured Up to 365 days
Incidence of clinically abnormal physical exam
measured Up to 365 days
Incidence of clinically abnormal electrocardiograms
measured Up to 365 days
Incidence of abnormal laboratory test results
measured Up to 365 days
Permalink · IRON's whole pipeline · Catalyst calendar · Every registered study · What changed